Literature DB >> 28057797

PRMT2 interacts with splicing factors and regulates the alternative splicing of BCL-X.

Mynol I Vhuiyan1, Magnolia L Pak1, Margaret A Park2, Dylan Thomas1, Ted M Lakowski3, Charles E Chalfant2,4,5, Adam Frankel1.   

Abstract

Protein arginine N-methyltransferase 2 (PRMT2) functions in JAK-STAT and Wnt/β-catenin signalling pathways, serves as a nuclear receptor-dependent transcriptional co-activator, and represses NF-κB and E2F1 transcription factor activities to promote apoptosis. We have previously demonstrated that PRMT2 interacts with PRMT1 and increases its activity. Here, we reveal associations using proteomics between the PRMT2 SH3 domain and splicing factors including Src-associated in mitosis 68 kDa protein (SAM68), a PRMT1 substrate and trans-acting factor that mediates BCL-X alternative splicing. We determined that PRMT2 interacts with SAM68 in cells and regulates its subcellular localization via the SH3 domain of PRMT2, prompting us to investigate the potential role of PRMT2 in BCL-X alternative splicing. We found that the expression of the full-length, wildtype form of PRMT2 promotes an increase in the BCL-X(L)/BCL-X(s) ratio in TNF-α or LPS stimulated cells. These results indicate that active PRMT2 may play a role during inflammation in alternative splicing regulation.
© The Authors 2017. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  BCL-X; PRMT2; SAM68; SH3 domain; alternative splicing

Mesh:

Substances:

Year:  2017        PMID: 28057797      PMCID: PMC5892402          DOI: 10.1093/jb/mvw102

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  43 in total

Review 1.  Control of apoptosis by Rel/NF-kappaB transcription factors.

Authors:  M Barkett; T D Gilmore
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  Protein arginine methylation facilitates cotranscriptional recruitment of pre-mRNA splicing factors.

Authors:  Yin-Chu Chen; Eric J Milliman; Isabelle Goulet; Jocelyn Côté; Christopher A Jackson; Jennifer A Vollbracht; Michael C Yu
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

3.  Kinetic analysis of human protein arginine N-methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-arginine residues on histone H4.

Authors:  Ted M Lakowski; Adam Frankel
Journal:  Biochem J       Date:  2009-06-26       Impact factor: 3.857

4.  Human protein arginine methyltransferases in vivo--distinct properties of eight canonical members of the PRMT family.

Authors:  Frank Herrmann; Peter Pably; Carmen Eckerich; Mark T Bedford; Frank O Fackelmayer
Journal:  J Cell Sci       Date:  2009-02-10       Impact factor: 5.285

5.  PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation.

Authors:  J Tang; J D Gary; S Clarke; H R Herschman
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

Review 6.  Protein arginine methylation in mammals: who, what, and why.

Authors:  Mark T Bedford; Steven G Clarke
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

Review 7.  SH3 domains: complexity in moderation.

Authors:  B J Mayer
Journal:  J Cell Sci       Date:  2001-04       Impact factor: 5.285

8.  Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing.

Authors:  Francois-Michel Boisvert; Jocelyn Cote; Marie-Chloe Boulanger; Patrick Cleroux; Francois Bachand; Chantal Autexier; Stephane Richard
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539

9.  PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145.

Authors:  Yanzhong Yang; Andrea Hadjikyriacou; Zheng Xia; Sitaram Gayatri; Daehoon Kim; Cecilia Zurita-Lopez; Ryan Kelly; Ailan Guo; Wei Li; Steven G Clarke; Mark T Bedford
Journal:  Nat Commun       Date:  2015-03-04       Impact factor: 14.919

10.  The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x.

Authors:  Maria Paola Paronetto; Tilman Achsel; Autumn Massiello; Charles E Chalfant; Claudio Sette
Journal:  J Cell Biol       Date:  2007-03-19       Impact factor: 10.539

View more
  7 in total

Review 1.  Relationship between protein arginine methyltransferase and cardiovascular disease (Review).

Authors:  Sisi Zheng; Congcong Zeng; Ailing Huang; Fuqi Huang; Anna Meng; Zhuan Wu; Shouhong Zhou
Journal:  Biomed Rep       Date:  2022-09-16

Review 2.  Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.

Authors:  Jia Cui; William J Placzek
Journal:  Int J Mol Sci       Date:  2018-01-20       Impact factor: 5.923

Review 3.  Protein arginine methylation: an emerging regulator of the cell cycle.

Authors:  Anita E Raposo; Sabine C Piller
Journal:  Cell Div       Date:  2018-03-20       Impact factor: 5.130

Review 4.  Arginine Methylation in Brain Tumors: Tumor Biology and Therapeutic Strategies.

Authors:  Jean-Paul Bryant; John Heiss; Yeshavanth Kumar Banasavadi-Siddegowda
Journal:  Cells       Date:  2021-01-11       Impact factor: 6.600

Review 5.  Competing Endogenous RNA (ceRNA) Networks and Splicing Switches in Cervical Cancer: HPV Oncogenesis, Clinical Significance and Therapeutic Opportunities.

Authors:  Afra Basera; Rodney Hull; Demetra Demetriou; David Owen Bates; Andreas Martin Kaufmann; Zodwa Dlamini; Rahaba Marima
Journal:  Microorganisms       Date:  2022-09-16

Review 6.  Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.

Authors:  Zhihui Dou; Dapeng Zhao; Xiaohua Chen; Caipeng Xu; Xiaodong Jin; Xuetian Zhang; Yupei Wang; Xiaodong Xie; Qiang Li; Cuixia Di; Hong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-12

Review 7.  mRNA Metabolism in Cardiac Development and Disease: Life After Transcription.

Authors:  Chen Gao; Yibin Wang
Journal:  Physiol Rev       Date:  2019-11-21       Impact factor: 37.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.